

(10-96)




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant.

* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/978,297	
			Filing Date	10/17/2001	
			First Named Inventor	Yacobi-Zeevi	
			Group Art Unit	1633	
			Examiner Name		
Sheet	3	Of	4	Attorney Docket Number	01/22716
✓	DA	Golberg et al, "An Improved Method For Determining Proteoglycans Synthesized by Chondrocytes in Culture", <i>Connective Tissue Research</i> , 24:265-275, 1990			
✓	DB	Farnsdale et al, "A Direct Spectrophotometric Microassay for Sulfated Glycosaminoglycans in Cartilage Cultures", <i>Connective Tissue Research</i> , 9:247-248, 1982			
✓	DC	Sutherland, Ian W., "Structure-Function Relationships in Microbial Exopolysaccharides", <i>Biotech Adv.</i> , 12:393-448, 1994			
✓	DD	Tatnell et al, "Characterisation of Alginates from Mucoïd Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 24:404S, 1996			
✓	DE	Tatnell et al, "Chemical Analysis of Alginates from Mucoïd Strains of <i>Pseudomonas Aeruginosa</i> ", <i>Biochem. Soc. Trans.</i> , 22:310S, 1994			
✓	DF	Tatnell et al, "Colonisation of Cystic Fibrosis Patients by Non-Mucoïd <i>Pseudomonas Aeruginosa</i> - Characterisation of the Alginate from Mucoïd Variants", <i>Biochem. Soc. Trans.</i> , 24:406S, 1996			
✓	DG	Drigues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide from a Virulent Strain of <i>Pseudomonas Solanacearum</i> and from Three Avirulent Mutants", <i>J Bacteriology</i> , May, 1985, pp 504-509			
✓	DH	Macone et al, "Mucoïd <i>Escherichia Coli</i> in Cystic Fibrosis", <i>New England J Medicine</i> , 304(24):14445-1449			
✓	DI	Ofek et al, "Bacterial Adhesion to Cells and Tissue", Chapman & Hall, N.Y., Pub. 1994, pp 114-118, 148-153, 418-418, 420-423			
	DJ				
Examiner Signature				Date Considered	11/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	09/978,297	
			Filing Date	10/17/2001	
			First Named Inventor	Yacobi-Zeevi	
			Group Art Unit	1633	
			Examiner Name		
Sheet	3	Of	4	Attorney Docket Number	01/22716
✓	CA	Konstan, Michael W., "Current Understanding of the Inflammatory Process in Cystic Fibrosis", <i>Pediatric Pulmonology</i> , 24:137-142, 1997			
	CB	Rubin, Bruce K., "Emerging Therapies for Cystic Fibrosis Lung Disease", <i>Chest</i> , 115:1120-1126, 1999			
✓	CD	Pasquier et al, "Implication of Neutral Polysaccharides Associated to Alginat Inhibition of Murine Macrophage Response to Pseudomonas Aeruginosa", <i>FEMS Microbiol Lett</i> , 1997 Feb 15; 147(2):195-202 (Abstract)			
✓	CE	Marty et al, "Influence of Nutrient Media on the Chemical Composition of Exopolysaccharide from Mucoid and Non-Mucoid Pseudom Aeruginosa", <i>FEMS Microbiol Lett</i> , 1992 Nov 1; 77(1-3):35-44 (Abstract)			
✓	CF	Drigues et al, "Comparative Studies of Lipopolysaccharide and Exopolysaccharide From a Virulent Strain of Pseudomonas Solanacearum and for Three Avirulent Mutants", <i>J Bacteriol</i> , 1985 May; 162(2):504-509 (Abstract)			
✓	CG	Jorba et al, "Variations in the P. Aeruginosa Polysaccharide Synthesis Conditioned by Aminosugars (author's transl), <i>Rev Esp Fisiol</i> , 1980 Jun; 36(2):155-161 (Abstract)			
✓	CH	Ramos et al, "Relationship Between Glycosis and Exopolysaccharide Biosynthesis in Lactococcus Lactis", <i>Appl Environ Microbiol</i> , 2001 Jan; 67(1):33-41 (Abstract)			
✓	CI	Bhaskar et al, "Dysregulation of Proteoglycan Production by Intrahepatic Epithelial Cells Bearing Defective (delta-f508) Cystic Fibrosis Transmembrane Conductance Regulator", <i>Hepatology</i> , 1998 Jan; 27(1):7-14 (Abstract)			
✓	CJ	Vogel et al, "Production Of Proteoglycans By Human Lung Fibroblasts (IMR-90) Maintained In A Low Concentration Of Serum", <i>Biochem J</i> 1982 Dec 1; 207(3):369-379. (Abstract)			
✓	CK	Hill et al, "Organ-Specific Over-Sulfation Of Glycosaminoglycans And Altered Extracellular Matrix In A Mouse Model Of Cystic Fibrosis", <i>Biochem Mol Med</i> , 1997 Oct;62(1):113-22. (Abstract)			
✓	CL	Welch et al, "Complex Saccharide Metabolism In Cystic Fibrosis Fibroblasts" <i>Pediatr Res</i> . 1975 Sep;9(9):698-702. (Abstract)			
✓	CM	Rahmoune et al, "Chondroitin Sulfate In Sputum From Patients With Cystic Fibrosis And Chronic Bronchitis", <i>Am J Respir Cell Mol Biol</i> . 1991 Oct;5(4):315-20. (Abstract)			
✓	CN	Beuth et al, "Lectin-Mediated Bacterial Adhesion To Human Tissue", <i>Eur J Clin Microbiol</i> , 1987 Oct;6(5):591-3. (Abstract)			
✓	CO	Allison et al, "Polysaccharide Production in Pseudomonas Cepacia", <i>J Basic Microbiol</i> , 1994; 34(1):3-10 (Abstract)			
✓	CP	Albus et al, "Staphylococcus Aureus Capsular Types And Antibody Response To Lung Infection In Patients With Cystic Fibrosis", <i>J Clin Microbiol</i> . 1988 Dec; 26(12):2505-9. (Abstract)			
✓	CQ	Macone et al, "Mucoid Escherichia Coli In Cystic Fibrosis", <i>N Engl J Med</i> . 1981 Jun 11;304(24):1445-9. (Abstract)			
Examiner Signature				Date Considered	11/9/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/978,297
				Filing Date	10/17/2001
				First Named Inventor	Yacobi-Zeevi
				Group Art Unit	1633
				Examiner Name	
Sheet	2	Of	4	Attorney Docket Number	01/22716
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹				T ²
RH	BA	"The Merck Manual", R. Berkow, M.D. Ed-in-Chief, Merck Research Laboratories, 1997, pp 201, 204, 1308, 177-179, 1016-1017, 194-197, 885, 601.			
	BB	Konstan et al, "Patterns of Medical Practice in Cystic Fibrosis: Part III. Use of Therapies", <i>Pediatr Pulmonol</i> , 1999, Oct; 28(4):248-54 (Abstract)			
	BC	Frederiksen et al, "Antibiotic Treatment of Initial Colonization with Pseudomonas Aeruginosa Postpones Chronic Infection and Prevents Deterioration of Pulmonary Function in Cystic Fibrosis", <i>Pediatr Pulmonol</i> , 1997 May; 23(5):330-335 (Abstract)			
	BD	Frederiksen et al, "Changing Epidemiology of Pseudomonas Aeruginosa infection in Danish Cystic Fibrosis Patients (1974-1995)", <i>Pediatr Pulmonol</i> , 1999 Sep; 28(3):159-166 (Abstract)			
	BE	Ramsey et al, "Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group", <i>N. Eng. J. Med.</i> , 1999 Jan 7; 340(1):23-30 (Abstract)			
	BF	Matzner et al, "Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils. Possible Role in Invasion Through Basement Membranes", <i>J. Clin. Invest.</i> , 1985 Oct; 76(4):1306-1313 (Abstract)			
	BG	Bennett et al, "Effect of Uridine 5'-Triphosphate plus Amiloride on Mucociliary Clearance in Adult Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1996 Jun; 153(6 Pt 1):1796-7801 (Abstract)			
	BH	Vlodavsky et al, "Expression Heparanase by Platelets and Circulating Cells of the Immune System: Possible Involvement in Diapedesis and Extravasation", <i>Invasion Metastasis</i> , 1992; 12(2):112-127 (Abstract)			
	BI	Naparstek et al, "Activated T Lymphocytes Produce a Matrix-Degrading Heparan Sulphate Endoglycosidase", <i>Nature</i> , 1984 July 19-25; 310(5974):241-244 (Abstract)			
	BJ	Armstrong et al, "Lower Airway Inflammation in Infants and Young Children with Cystic Fibrosis", <i>Am J Respir Crit Care Med</i> , 1997 Oct; 156(4Pt 1):1197-1204 (Abstract)			
	BK	Tang et al, "Contribution of Specific Pseudomonas Aeruginosa Virulence Factors to Pathogenesis of Pneumonia in a Neonatal Mouse Model of Infection", <i>Infect Immun</i> , 1996 Jan; 64(1):37-43 (Abstract)			
	BL	Murray et al, "The Extracellular Matrix", found in Harper's Biochemistry, 24 th Ed., McGraw-Hill Professional 1998, Chap. 57, pp 667-679			
	BM	Selvan et al, "Heparan Sulfate in Immune Responses", <i>Annals New York Academy of Sciences</i> , 797:127-139, 1996			
RH	BN	Weller, Peter H., "Implications of Early Inflammation and Infection in Cystic Fibrosis: A Review of New and Potential Interventions", <i>Pediatric Pulmonology</i> , 24:143-146, 1997			
Examiner Signature				Date Considered	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. In this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3)

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TECH CENTER 1-800-2900

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.